Table 1.
Revised Scoring System for the Diagnosis of Autoimmune Hepatitis6.
| Parameter/Features | Score |
| Gender | |
| - Female/Male | +2/0 |
| Degree of elevation above upper normal limit of ALP vs. aminotransferases | |
| - <1.5 | +2 |
| - 1.5 – 3.0 | 0 |
| - >3.0 | -2 |
| Total serum globulins, γ-globulins, or IgG above normal | |
| - >2.0 | +3 |
| - 1.5 – 2.0 | +2 |
| - 1.0 – 1.5 | +1 |
| - <1.0 | 0 |
| ANA, SMA or LKM-1 (titers by immunofluorescence on rodent tissues or HEp2-cells) | |
| - >1 : 80 | +3 |
| - 1 : 80 | +2 |
| - 1 : 40 | +1 |
| - <1 : 40 | 0 |
| - AMA positive | -4 |
| Hepatitis viral markers (IgM anti-HAV, HBsAg, IgM anti-HBc, anti-HCV and HCV-RNA) | |
| - Positive/Negative | -3/+3 |
| Recent or current use of known or suspected hepatotoxic drugs | |
| - Yes/No | -4/+1 |
| Average alcohol intake | |
| - <25 g/day | +2 |
| - >60 g/day | -2 |
| Other autoimmune disease(s) in patient or first degree relatives | |
| - Yes/No | +2/0 |
| Optional additional parameters (should be allocated only if ANA, SMA or LKM-1 are negative) | |
| - HLA DR3, DR4, or other HLA with published association with AIH) | +1 |
| - Seropositivity for any of ANCA, anti-LC1, anti-SLA/LP, anti-ASGPR and anti-sulfatide | +2 |
| Liver histology | |
| - Interface hepatitis | +3 |
| - Predominant lymphoplasmacytic infiltrate | +1 |
| - Rosetting of liver cells | +1 |
| - None of the above | -5 |
| - Biliary changes | -3 |
| - Other changes | -3 |
| Response to therapy (as defined in Table 2) | |
| - Complete/Relapse | +2/+3 |
Definite AIH if greater than 15 before treatment or greater than 17 post-treatment; probable AIH if varies between 10–15 before treatment or 12–17 post-treatment. ALP: alkaline phospatase, IgM anti-HAV: hepatitis A virus IgM antibody, anti-HCV: hepatitis C virus antibody, HBsAg: surface antigen of hepatitis B virus, IgM anti-HBc: IgM antibody against the nuclear antigen of hepatitis B virus. Other abbreviations are the same as shown in the text.